# Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

> **NCT00533390** · PHASE4 · TERMINATED · sponsor: **Oswaldo Cruz Foundation** · enrollment: 130 (actual)

## Conditions studied

- Tuberculosis
- HIV Infections

## Interventions

- **DRUG:** efavirenz

## Key facts

- **NCT ID:** NCT00533390
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** Lack of financial support and low inclusion rate
- **Last updated:** 2015-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533390, "Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00533390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*